Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jun 15, 2014; 5(3): 235-243
Published online Jun 15, 2014. doi: 10.4239/wjd.v5.i3.235
Published online Jun 15, 2014. doi: 10.4239/wjd.v5.i3.235
Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia
Hyun Joon Paek, Courtney Kim, Biologics, Tissue Genesis Institute, LLC, Honolulu, HI 96813, United States
Stuart K Williams, Cardiovascular Innovation Institute, University of Louisville, Louisville, KY 40202, United States
Author contributions: Paek HJ wrote the manuscript; Kim C and Williams SK reviewed and revised it.
Correspondence to: Hyun Joon Paek, PhD, Director, Biologics, Tissue Genesis Institute, LLC, 810 Richards Street, Suite 1000, Honolulu, HI 96813, United States. jpaek@tissuegenesis.com
Telephone: +1-808-7725590 Fax: +1-808-5595339
Received: December 12, 2013
Revised: January 30, 2014
Accepted: May 8, 2014
Published online: June 15, 2014
Revised: January 30, 2014
Accepted: May 8, 2014
Published online: June 15, 2014
Core Tip
Core tip: Adipose-derived stem cells (ADSCs) can provide a promising cell therapy for treatment of diabetes and associated complications. ADSCs’ multipotency allows differentiation into insulin-producing β-cells. Anti-inflammatory and immunomodulatory capabilities of ADSCs can facilitate enhanced engraftment of transplanted donor islets. Although many challenges lie ahead for ADSC-based cell therapies are used clinically to treat diabetic hyperglycemia, ADSCs represent a novel treatment option to many diabetic patients worldwide.